Inozyme Pharma Files 8-K Report
| Field | Detail |
|---|---|
| Company | Inozyme Pharma, Inc. |
| Form Type | 8-K |
| Filed Date | Jun 23, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, filing, disclosure
Related Tickers: INOZ
TL;DR
INOZ files 8-K, likely with material updates. Watch for details.
AI Summary
On June 20, 2025, Inozyme Pharma, Inc. filed an 8-K report. The filing indicates that the company is providing information regarding "Other Events" and "Financial Statements and Exhibits." No specific details about these events or financial statements were provided in the excerpt.
Why It Matters
This 8-K filing signals that Inozyme Pharma has made a significant public disclosure, potentially related to material events or financial updates that could impact investors.
Risk Assessment
Risk Level: medium — 8-K filings often contain material information that can significantly impact a company's stock price, requiring investor attention.
Key Players & Entities
- Inozyme Pharma, Inc. (company) — Registrant
- June 20, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- 001-39397 (other) — Commission File Number
- 321 Summer Street, Suite 400, Boston, Massachusetts 02210 (address) — Principal Executive Offices
- (857) 330-4340 (phone_number) — Registrant's Telephone Number
FAQ
What specific "Other Events" are being reported by Inozyme Pharma, Inc. on June 20, 2025?
The provided excerpt of the 8-K filing does not specify the details of the "Other Events."
What is the nature of the "Financial Statements and Exhibits" being filed by Inozyme Pharma, Inc.?
The excerpt does not provide details on the specific financial statements or exhibits being filed.
When was Inozyme Pharma, Inc. incorporated, and in which jurisdiction?
Inozyme Pharma, Inc. was incorporated in Delaware.
What is the principal executive office address for Inozyme Pharma, Inc.?
The principal executive office is located at 321 Summer Street, Suite 400, Boston, Massachusetts 02210.
What is the Commission File Number for Inozyme Pharma, Inc.?
The Commission File Number for Inozyme Pharma, Inc. is 001-39397.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 23, 2025 regarding Inozyme Pharma, Inc..